1,823
Views
7
CrossRef citations to date
0
Altmetric
Research Paper

Hypothetical assessment of efficiency, willingness-to-accept and willingness-to-pay for dengue vaccine and treatment: a contingent valuation survey in Bangladesh

ORCID Icon, ORCID Icon & ORCID Icon
Pages 773-784 | Received 26 Apr 2020, Accepted 12 Jul 2020, Published online: 21 Aug 2020

References

  • Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–07. doi:10.1038/nature12060.
  • Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue’ a systematic analysis. Lancet Infect Dis. 2016;16(8):935–41. doi:10.1016/S1473-3099(16)00146-8.
  • Ferrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ. Monson`s tropical infectious diseases. ELSEVIER; 2014.
  • World Health Organization. Comprehensive guideline for prevention and control of dengue and dengue haemorrhagic fever. Geneva; 2011.
  • WHO, Regional strategic plan for integrated neglected tropical diseases control in South-East Asia Region, 2012-2016, SEA-CD-250 (2012).
  • Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6(8):e1760. doi:10.1371/journal.pntd.0001760.
  • Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomized, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67. doi:10.1016/S0140-6736(12)61428-7.
  • Bhatia R, Dash A, Sunyoto T. Changing epidemiology of dengue in South-East Asia. WHO-SEAJPH. 2013;2(1):23–27. doi:10.4103/2224-3151.115830.
  • Messina JP, Brady OJ, Scott TW. Global spread of dengue virus types: mapping the 70 years history. Trends Microbiol. 2014;22(3):138–46. doi:10.1016/j.tim.2013.12.011.
  • Sharmin S, Viennet E, Glass K, Harley D. The emergence of dengue in Bangladesh: epidemiology, challenges, and future disease risk. Trans R Soc Trop Med Hyg. 2015;109(10):619–27. doi:10.1093/trstmh/trv067.
  • Mutsuddy P, Jhora ST, Shamsuzzaman AKM, Kaisar SMG, Khan MNA. Dengue situation in Bangladesh: an epidemiological shift in terms of morbidity and mortality, Hindawi. CJIDMM. 2019;3516284:1–12.
  • Sharmin S, Glass K, Viennet E, Harley D. Geostatistical mapping of the seasonal spread of under-reported dengue cases in Bangladesh. PLoS, Negl Trop Dis. 2018;12(11):e0006947. doi:10.1371/journal.pntd.0006947.
  • DeRoeck D, Deen J, Clemens JD. Policymakers views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four Southeast Asian countries. Vaccine. 2003;22(1):121–29. doi:10.1016/S0264-410X(03)00533-4.
  • Vannice KS, Durbin A, Hombach J. Status of vaccine research and development of vaccines for dengue. Vaccine. 2016;34(26):2934–38. doi:10.1016/j.vaccine.2015.12.073.
  • Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL. Live-attenuated tetravalent dengue vaccines: the needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine. 2017;35(42):5535–42. doi:10.1016/j.vaccine.2017.08.066.
  • Sanofi’s dengue vaccine approved in 11 countries. Reuters. 2016. [accessed 2017 August 13].
  • East S. World’s first dengue fever vaccine launched in the Philippines. CNN. [accessed 2016 October 17].
  • Zachri E, Planasari S. Dengue fever vaccine available in Indonesia. WIB, [accessed 2016 October 17].
  • Thomas SJ, Yoon IK. A review of Dengvaxia®: development to deployment. Hum Vacc Imm. 2019;15(10):2295–314. doi:10.1080/21645515.2019.1658503.
  • Silveira LTC, Tura B, Santos M. Systematic review of dengue vaccine efficacy. BMC Infect Dis. 2019;19(750). doi:10.1186/s12879-019-4369-5.
  • World Health Organization, Regional office for the Western Pacific. Dengue situation update 2020. 2020. http://iris.wpro.who.int/handle/10665.1/14461
  • Dengue vaccine: WHO position paper – September 2018. Weekly Epidemiological Record. 2018 September 7;93(36):457–76.
  • Tricou V, Sáez-Llorens X, Yu D, Rivera L, Jimeno J, Villarreal AC, Dato E, de Suman OS, Montenegro N, DeAntonio R, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomized, placebo-controlled, phase 2 trial. LANCET. 2020;395(10234):1434–43. doi:10.1016/S0140-6736(20)30556-0.
  • Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo-controlled, phase 3 trial. LANCET. 2020;395(10234):1423–33. doi:10.1016/S0140-6736(20)30414-1.
  • Harapan H, Fajar JK, Sasmono RT, Kuch U. Dengue vaccine acceptance and willingness to pay. Hum Vaccin Immunother. 2017;13(4):786–90. doi:10.1080/21645515.2016.1259045.
  • Palanca-Tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. Vaccine. 2008;26(7):914–23. doi:10.1016/j.vaccine.2007.12.011.
  • Hadsoemarto PF, Castro MC. Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia. PloS Negl Trop Dis. 2013;7(9):e2427. doi:10.1371/journal.pntd.0002427.
  • Harapan H, Anwar S, Bustamam A, Radiansyah A, Angraini P, Fasli R, Salwiyadi S, Bastian RA, Oktiviyari A, Akmal I, et al. Willingness to pay for a dengue vaccine and its associated determinants in Indonesia: a community-based, cross-sectional survey in Aceh. Acta Trop. 2017;166:249–56. doi:10.1016/j.actatropica.2016.11.035.
  • Lee J-S, Mogasale V, Lim JK, Carabali M, Sirivichayakul C, Anh DD, Lee K-S, Thiem VD, Limkittikul K, Tho LH, et al. A multi-country study of the household willingness-to-pay for dengue vaccines: household surveys in Vietnam, Thailand, and Colombia. PloS Negl Trop Dis. 2015;9(6):e0003810. doi:10.1371/journal.pntd.0003810.
  • Godoi IP, Santos AS, Reis EA, Lemos LLP, Brandão CMR, Alvares J, Acurcio FA, Godman B, Guerra Júnior AA. Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia(R)) bin Brazil; implications for future pricing considerations. Front Pharmacol. 2017;8:41. doi:10.3389/fphar.2017.00041.
  • Yeo HY, Shafie AA. The acceptance and willingness to pay (WTP) for hypothetical dengue vaccine in Penang, Malaysia: a contingent valuation study. BMC Cost Eff Res Allo. 2018;16(60).
  • Dhiman M, Aryal KK, Dhimal ML, Gautam I, Sing SP, Bhusal CL, Kuch U. Knowledge, attitude, and practice regarding dengue fever among the healthy population of highland and lowland communities in central Nepal. Plos One. 2014;9(7):e102028. doi:10.1371/journal.pone.0102028.
  • Lam H, Ku GM, Wu D, Cheng KJG, Rivera A, Tumanan-Mendoza B, Alejandria M. Cost-effectiveness analysis of dengue vaccination in the Philippines. Int J Infect Dis. 2016;45:421. doi:10.1016/j.ijid.2016.02.897.
  • Zeng W, Halasa-Rappel YA, Baurin N, Coudeville L, Shepard D. Cost-effectiveness of dengue vaccination in ten endemic countries. Vaccine. 2018;36(3):413–20. doi:10.1016/j.vaccine.2017.11.064.
  • Okanurak K, Sornmani S, Mas-ngammueng R, Sitaputra P, Krachangsang S, Limsomboon J. Treatment seeking behavior of DHF patients in Thailand. Southeast Asian J Trop Med Pub Health. 1997;28:351–58.
  • Tran BX, Nguyen NK, Nguyen LP, Nguyen CT, Nong VM, Nguyen LH. Preference and willingness to pay for traditional medicine services in rural ethnic minority community in Vietnam. BMC Complement Altern Med. 2016;16(1):48. doi:10.1186/s12906-016-1010-7.
  • Pang J, Salim A, Lee VJ, Hibbert ML, Chia KS, Leo YS, Lye DC. Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study. PLoS Negl Trop Dis. 2012;6(5):e1641. doi:10.1371/journal.pntd.0001641.
  • Gibson G, Souza-Santos R, Honório NA, Pacheco AG, Moraes MO, Kubelka C, Brasil P, Cruz O, Carvalho MS. Conditions of the household and peridomicile and severe dengue: a case control in Brazil. Infect Ecol Epidemiol. 2014;4:1–7.
  • Nealon J, Lim WY, Moureau A, Linus Lojikip S, Junus S, Kumar S, Nachiappan JP, Devi Sekaran S, Radigue C, Cowling BJ, et al. Feasibility of case-control and test negative designs to evaluate dengue vaccine effectiveness in Malaysia. Vaccine. 2019;37(39):5891–98. doi:10.1016/j.vaccine.2019.07.083.
  • Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Hj Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–206. 26214039. doi:10.1056/NEJMoa1506223.
  • Population & Housing Census-2011 (PDF). Bangladesh Bureau of Statistics. p. 41. Archived from the original (PDF) on 8 December 2015, [accessed December 2015 15].
  • Dhaka Population. World population review. October 2018. [accessed March 2019 18].
  • Kuga K, Tanimoto J. Impact of imperfect vaccination and defense against contagion on vaccination behavior in complex networks. Jstate. 2018;113402(11).
  • Kabir KMA, Kuga K, Tanimoto J. Effect of information spreading to suppress the disease contagion on the epidemic vaccination game. Cha. Sol Frac. 2019;119:180–87. doi:10.1016/j.chaos.2018.12.023.
  • Kabir KMA, Tanimoto J. Dynamical behaviors for vaccination can suppress infectious disease - a game theoretical approach, Cha. Sol Frac. 2019;123:229–39. doi:10.1016/j.chaos.2019.04.010.
  • Lee JS, Mogasale V, Lim JK, Carabali M, Lee K-S, Sirivichayakul C, Dang DA, Palencia-Florez DC, Nguyen THA, Riewpaiboon A. A multi-country study of the economic burden of dengue fever: vietnam, Thailand, and Colombia. PLoS Negl Trop Dis. 2017;11(10):e0006037. doi:10.1371/journal.pntd.0006037.
  • Harapan H, Anwar S, Setiawan AM, Sasmono R. Aceh dengue study. Dengue vaccine acceptance and associated factors in Indonesia: a community based cross-sectional survey in Aceh. Vaccine. 2016;34(32):3670–75. doi:10.1016/j.vaccine.2016.05.026.
  • Palanca-Tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. Vaccine. 2006;26(7):914–23. doi:10.1016/j.vaccine.2007.12.011.
  • Bracho-Churio YT, Martinez-Vega RA, Rodriguez-Morales AJ, Diaz-Quijano RG, Luna-Gonzalez ML, Diaz-Quijano FA. Determinants of felt demand for dengue vaccines in the North Caribbean region of Colombia. Ann Clin Microbiol Antimicrob. 2017;16(1):38. doi:10.1186/s12941-017-0213-1.
  • Nguyen LH, Tran BX, Do CD, Hoang CL, Nguyen TP, Dang TT, Thu Vu G, Tran TT, Latkin CA, Ho CS, et al. Feasibility and willingness to pay for dengue vaccine in the thread of dengue fever outbreaks in Vietnam. Patient Preference Adherence. 2018;12:1917–26. doi:10.2147/PPA.S178444.
  • The daily star, Dengue Vaccine: Relief turns into worry. 2017. https://www.thedailystar.net/frontpage/dengue-vaccine-relief-turns-worry-1507933

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.